8th International Wolfram Symposium Presentation Liiv M1, Vaarmann A1, Kuum M1, Gupta-Blixt R1, Janickova L1, Hodurova Z1, Cagalinec M1, Zeb A1, Choubey V1, Hickey MA1, Safiulina D1, Yi-Long H2, Gogichaisvili N1, Mandel M1, Plaas M1, Vasar E1, Loncke J3, Vervliet T3, Tsai T-F2, Bultynck G3, Veksler V4, Kaasik A1.1Departments of Pharmacology and Physiology, University of Tartu, Estonia. 2Department of Life Sciences, National Yang Ming Chiao Tung University, Taiwan 3Laboratory of Molecular and Cellular Signaling, KU Leuven, Belgium. 4INSERM UMR-S 1180, University Paris-Saclay, France.

8th International Wolfram Symposium Presentation Liiv M1, Vaarmann A1, Kuum M1, Gupta-Blixt R1, Janickova L1, Hodurova Z1, Cagalinec M1, Zeb A1, Choubey V1, Hickey MA1, Safiulina D1, Yi-Long H2, Gogichaisvili N1, Mandel M1, Plaas M1, Vasar E1, Loncke J3, Vervliet T3, Tsai T-F2, Bultynck G3, Veksler V4, Kaasik A1.1Departments of Pharmacology and Physiology, University of Tartu, Estonia. 2Department of Life Sciences, National Yang Ming Chiao Tung University, Taiwan 3Laboratory of Molecular and Cellular Signaling, KU Leuven, Belgium. 4INSERM UMR-S 1180, University Paris-Saclay, France.
Pharmacological targets to correct deficient ER-mitochondrial Ca2+ homeostasis in the neuronal models of Wolfram Syndrome
Abstract: Wolfram syndrome (WS) is a rare genetic disease caused by mutations in the WFS1 or CISD2 gene. A primary defect in WS involves poor endoplasmic reticulum (ER) Ca2+ handling, but how this disturbance leads to the disease is not known. Although the clinical symptoms of WS resemble mitochondrial diseases and WFS1 or CISD2 deficiency leads to mitochondrial abnormalities, no causal link has been established between the ER defects, mitochondrial dysfunction and cell metabolic disturbances. The current study, performed in primary isolated neurons, the most affected and disease-relevant cells, involving both WS genes explains how the disturbed ER Ca2+ handling compromises mitochondrial function and in turn affects neuronal health. Loss of ER Ca2+ content in the axons of the WFS1 or CISD2 deficient neurons is associated with lower IP3R3-mediated Ca2+ transfer from ER to mitochondria leading to decreased mitochondrial Ca2+ uptake. In turn, reduction in mitochondrial Ca2+ content inhibits mitochondrial ATP production leading to an increased axoplasmic NADH/NAD+ ratio. The resulting bioenergetic deficit and reductive stress further compromise the neurons health. Our work also identifies pharmacological targets and compounds that potentially may restore Ca2+ homeostasis, enhance mitochondrial function and improve neuronal function.
Points noted:
•  Compounds affecting ER and mitochondrial Ca2+ could improve mitochondrial function and neuronal health.
•  WS serves as an important disease prototype for ER and mitochondrial dysfunction.
•  Hope to publish findings soon.
/by

8th International Wolfram Symposium Presentation Fumihiko Urano, MD, PhD, Samuel E. Schechter Professor of Medicine, Washington University School of Medicine, St. Louis, USA

8th International Wolfram Symposium Presentation Fumihiko Urano, MD, PhD, Samuel E. Schechter Professor of Medicine, Washington University School of Medicine, St. Louis, USA
 
Novel Therapies for Wolfram Syndrome
 
Abstract: Wolfram syndrome is a rare genetic spectrum disorder characterized by insulin-dependent diabetes, optic nerve atrophy, and progressive neurodegeneration, and ranges from mild to severe clinical symptoms. There is currently no treatment to delay, halt, or reverse the progression of Wolfram syndrome, raising the urgency for innovative therapeutics for this disease. Here, we summarize our vision and progress on developing novel treatments and achieving a cure for Wolfram syndrome. Our approach entails utilizing oral pharmacotherapy aimed at modulating endoplasmic reticulum and mitochondrial functions to impede the progression of the disease, followed by the implementation of gene therapy to arrest its advancement, ultimately culminating in the application of regenerative therapy using a unique neurotrophic factor, MANF, and iPSC-derived tissues for the repair of any damaged tissues, especially retinal ganglion cells and brain cells. Our proposed approach has the potential to not only alleviate the symptoms of Wolfram syndrome, but it may also lead to a potential cure for medical conditions commonly seen in Wolfram syndrome, including diabetes, vision loss, and neurodegeneration. This is due to the innovative nature of our strategy, which targets the root cause of Wolfram syndrome, thereby offering a universal solution for a wide range of human chronic disorders.
 
Points noted:
•  Dr Urano is working with many collaborators. The team have medical records for +250 patients (2009-present) and long-term data for +50 patients (2011- present).
•  There is an increased understanding of this rare disease.
Look to identify patient cohorts for clinical trials and the best outcome measures.
•  Previous dantrolene clinical study showed improved beta cell function in a subset of patients. Patients with greatest increase tended to have visual acuity and less severe disease.
•  AMX-0035 – preclinical studies have confirmed that this combination therapy performs better than a single agent (e.g. reduced cell death and improved mitochondrial function). First clinical trial initiated in April 2023 with C-peptide as the primary outcome measure.
•  S1R agonist (Pridopidine) is being tested in pre-clinical models (through collaboration with Prilenia).
•  Working with an industry partner on gene therapies and gene editing with Prof Catherine Verfaillie. Willing to share protocol for iPSCs models with other researchers.
•  Shared WS mutant rodent (rat and mice) models with other researchers and is willing to share with additional researchers who would like them.
•  For entrepreneurship, need industry partners, which are also needed in Europe (current industry collaborators are US companies).
/by

8th International Wolfram Symposium Presentation Prof Timothy Barrett, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham UK, on behalf of the TREATWOLFRAM investigators (Dr Renuka Dias, Dr Ben Wright (UK), Dr Gema Esteban Bueno (Spain), Prof Wojciech Mlynarski (Poland), Dr Christophe Orssaud, Prof Agathe Roubertie (France)

8th International Wolfram Symposium Presentation Prof Timothy Barrett, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham UK, on behalf of the TREATWOLFRAM investigators (Dr Renuka Dias, Dr Ben Wright (UK), Dr Gema Esteban Bueno (Spain), Prof Wojciech Mlynarski (Poland), Dr Christophe Orssaud, Prof Agathe Roubertie (France)
 
Sodium Valproate efficacy and safety in WFS1 Spectrum Disorder (TREATWOLFRAM). Update on phase II pivotal international multicentre, double-masked, randomised controlled trial.
 
ABSTRACT: Introduction
WFS1 spectrum disorder (WFS1-SD) comprises a classic form of progressive neurodegenerative disorder, formerly known as Wolfram syndrome, and non-classic forms including low-frequency sensorineural hearing loss. This is the commonest monogenic syndrome of diabetes and vision impairment, affecting 1:500,000 in the UK. Despite this, there are no licensed pharmacological therapies for WFS1-SD. Sodium valproate (VPA) is an anti-convulsant approved for use for the treatment of epilepsy and bipolar disorder. VPA has been shown to reduce Endoplasmic Reticulum (ER) stress, is known to exert neuroprotective effects in models of neurodegeneration, and in the context of WFS1-SD, VPA is thought to mediate its effect via alteration of cell cycle kinetics, increase in p21cip1 expression levels or nuclear translocation and reduction in apoptosis, and increase in Wolfram protein expression. There is currently a lack of prospective controlled studies investigating therapeutic candidates in people with WFS1-SD.
 
Methods
TREATWOLFRAM is a phase II, pivotal, international multi-centre, double-masked, placebo-controlled, randomised clinical trial designed to investigate whether a 36 month treatment with up to 800mg/day of VPA in children aged 6-12 years, or up to 1600mg/day for those aged 12 years of over, will slow the rate of change in visual acuity as assessed by corrected visual acuity in each eye, using standardised charts, in participants with WFS1-SD. Children aged 6 years or more and adults with genetically confirmed WFS1-SD and visual acuity with LogMAR score of 1.6 or better on an EDTRS chart, were assessed for eligibility at 6 recruitment centres in Europe. Patients who satisfied the eligibility criteria were randomly assigned (2:1) to receive twice daily tablets of either VPA or VPA-placebo (control). Analysing visual acuity outcomes using longitudinal hierarchical models, and using data on a cohort of 26 patients with Wolfram syndrome kindly provided by Prof Tamara Hershey, (significance level 0.05, power 0.90), and accounting for an estimated 15% withdrawal rate, we estimated a target sample size of 70 patients, so that a minimum of 21 participants were randomised to each treatment group. The primary outcome measure will be centrally assessed using an intention-to-treat analysis of the proportion of evaluable participants achieving a decline in the rate of progression of vision loss between baseline and after 36 months of treatment. Visual acuity progression will be defined as the change in LogMAR units over time as measured on EDTRS charts.
 
Ethics and dissemination
The protocol was designed with assistance from the EU Committee for Medicinal Products for Human Use (CHMP) and approved by The West of Scotland Research Ethics Service (18/WS/0020) and The Medicines and Healthcare Products Regulatory Agency (EudraCT 2017-001215-37; ISRCTN 10176118). Recruitment into TREATWOLFRAM started in January 2019 and ended in October 2021, with 63 patients randomised. The treatment follow-up of TREATWOLFRAM patients is currently ongoing and due to finish in October 2024. The findings of this trial will be disseminated through peer-reviewed publications.
 
Trial registration: Clinicaltrials.gov NCT03717909 Points noted:
•  Visual acuity is the primary endpoint of TreatWolfram. A number of secondary endpoints are also included.
•  Sodium valproate targets the final part of the treatment pathway. This drug has decades of use, has been shown to be neuroprotective and as it is off- patent – there is freedom to operate in clinical trials and ongoing licensing.
•  TreatWolfram received 2014 orphan drug designation by EMA and FDA. Regulators may not require a gold standard double blind randomised controlled trial today.
•  The trial was delayed by a range of issues – as a result some patients were unable to participate as their vision had deteriorated while awaiting trial commencement.
•  If starting the study today, Milan would be included as a study site (this group has been developing a clinical trial centre).
•  University of Birmingham now has an established clinical trial unit for delivering pivotal trials in rare disease and a network of trial sites that would like to be included in future WS clinical trials in Europe.
•  The study clearly highlighted that Brexit has been damaging for rare disease research.
•  Better biomarkers are needed that can demonstrate efficacy in around 6 months that are relevant for patients. Researchers need to be able to identify responders to potential treatments in a much shorter timeframe.
•  With better biomarkers, new clinical trials could be designed to report in a shorter timeframe (and should therefore be less expensive). This could help attract more commercial partners into WS clinical research.
•  It was noted patient samples will be available to help assist in developing biomarkers, including placebo data from clinical trials.
/by

8th International Wolfram Symposium Presentation Dr Christophe Orssaud – Functional Unit of Ophthalmology, Paris, France

8th International Wolfram Symposium Presentation Dr Christophe Orssaud – Functional Unit of Ophthalmology, Paris, France
Audiowolf : Description, contribution and interest of this protocol
Alongside the Treatwolfram protocol initiated by Pr T Barrett, a second new protocol has been initiated in France, called Audiowolf. These two protocols are similar in terms of their duration (3 years), the patients for whom they are intended (patients with Wolfram syndrome) and the molecule used (sodium valproate). They nevertheless differ by several points which make them complementary.
These differences relate first to the primary judgment criterion. This primary judgment criterion is auditory in Audiowolf and not visual. It is also a non-randomized protocol without double blinding. All the patients included receive the treatment at a dose adapted to their weight. Finally, it was initially designed as being monocentric (Paris), although it is currently undergoing extension to Spain (Almeria).
However, this Audiowolf protocol is not a competitor but rather complementary to Treatwolfram. Indeed, it makes it possible to include patients who did not meet the inclusion criteria of the Treatwolfram protocol due to too low visual acuity. On the other hand, the auditory, visual, neuro-radiological and biological tests are identical. Thus, after a separate processing of both protocols, these different data can be combined for common analyses. Finally, this protocol will make it possible to better analyze the auditory impairment of Wolfram syndrome. On the other hand, all patients receiving sodium valproate, an ancillary study was initiated to understand how this molecule may affect insulin regulation.
In practice, the inclusion criteria require, among other things, a hearing impairment of at least 5 dB at 8000 Hz. And this protocol can be delivered “turnkey” to teams that would like to propose it to their patients.
Points noted:
•  Patients enrolled in this study must have some level of hearing loss (those with hearing implants can be included).
•  Study first started in Nov 2021 – after TreatWolfram (to avoid patients needing to choose which study to participate in).
•  Secondary objective of the study is to evaluate C-peptide to try to understand how sodium valproate acts on insulin secretion.
•  A rare side effect of sodium valproate is hearing loss, which is typically bilateral and reversible. This will need to be considered should any patients experience severe hearing loss during the study (patient data likely to be excluded, at least initially).
/by

8th International Wolfram Symposium Presentation Prof Catherine Verfaillie – Stem Cell Institute, KU Leuven, Belgium

8th International Wolfram Symposium Presentation Prof Catherine Verfaillie – Stem Cell Institute, KU Leuven, Belgium
 
iPSC-based modeling of Wolfram Syndrome and therapeutic genome editing approaches
 
Points noted:
•  Developed iPSC-based models of different cell types – neural cells, ganglion, astrocytes, and blood brain barrier endothelial cells.
•  These cell lines can be shared with other WS researchers who would like to use them.
•  Further evaluate (e.g. myelination, stain for different markers) and explore changes over time. Also compare with WS-derived models to explore differences.
•  Base editing conducted using this system – look to see if / how this can be delivered in vivo.
•  Translate findings to mouse model – exchange with Fumi (Dr Urano) mouse model with current iPSC system.
/by

8th International Wolfram Symposium Presentation Mathias Leinders – Amylyx Pharmaceuticals 

8th International Wolfram Symposium Presentation Mathias Leinders – Amylyx Pharmaceuticals 

Helios – A Phase II Study of Safety and Efficacy of AMX0035 in Wolfram Syndrome

Summary: Update on the clinical trial design of Helios, and the rationale for using AMX0035 as potential treatment for Wolfram Syndrome. 

Points noted: 

  • AMX0035 is a combination therapy of two compounds– TUDCA (tauroursodeoxycholic acid) and sodium phenylbutyrate (PB). 
  • Approved in the US for ALS, not currently approved in the EU. 
  • Investigational drug for WS. Received orphan drug status in US. 
  • Shown to decrease neuronal death, mitigate ER stress and mitochondrial dysfunction. 
  • Excellent safety and tolerability profile shown in previous studies (Ph III in ALS). Taste issues have been reported previously (AMX0035 = sachet). 
  • Currently conducting a collaboration with Dr Urano (preclinical and clinical). 
  • As part of this collaboration, an open label Ph II study has started in US to recruit 12 patients to assess safety (using standard endpoints), tolerability, various measurements (e.g. beta cell function), and exploratory biomarkers. 
  • Study will monitor C-peptide levels (as a surrogate endpoint) over 24-week period. Patients will therefore need to be relatively healthy to be able to participate (It was noted that not many patients will meet the inclusion criteria required for C-peptide levels). Based on learnings from the dantrolene trial, the target of 12 patients should be achieved. 
  • The study aims to assess whether there is value in treating WS patients as early as possible and if data are encouraging will expand to larger and longer studies. 
  • The study protocol includes a 4-hour mixed meal tolerance test (MMTT) (which it was noted is a big ask for patients and researchers). This test was specifically requested by the FDA. If data are encouraging, the aim is to propose to reduce MMTT in a future larger trial. 
  • If data are encouraging, this will help to spur development in a juvenile programme. 
  • First patient recruited to this study April 2023 (week prior to the Symposium). 
/by